The analysis is based on results from the STEP 1 trial, published in 2021 in the New England Journal of Medicine , which showed the 2.4 mg dosage of semaglutide approved by the FDA for the treatment of obesity reduced body weight by an average of 14.9% along with reductions in several cardiovascular risk factors such as blood pressure and lipids
As a result, this study can only report the frequency and proportional distribution of AEs, not their true incidence
Tirzepatide is a dual GIP and GLP-1 receptor agonist, which means it mimics two natural gut hormones that help regulate appetite, digestion, and blood sugar
There are several practical strategies that can help manage cold sensitivity whilst continuing tirzepatide therapy
Basal metabolic rate drops accordingly
and people with alcohol dependence 79